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Kaiso is a BTB domain protein that associates with the signaling molecule p120-catenin and binds to the
methylated sequence mCGmCG or the nonmethylated sequence CTGCNA to modulate transcription. In Xenopus
laevis, xKaiso deficiency leads to embryonic death accompanied by premature gene activation in blastulae and
upregulation of the xWnt11 gene. Kaiso has also been proposed to play an essential role in mammalian synapse-
specific transcription. We disrupted the Kaiso gene in mice to assess its role in mammalian development. Kaiso-null
mice were viable and fertile, with no detectable abnormalities of development or gene expression. However, when
crossed with tumor-susceptible ApcMin/ mice, Kaiso-null mice showed a delayed onset of intestinal tumorigenesis.
Kaiso was found to be upregulated in murine intestinal tumors and is expressed in human colon cancers. Our data
suggest that Kaiso plays a role in intestinal cancer and may therefore represent a potential target for therapeutic
intervention.
The methyl-CpG binding proteins act as intermediates be-
tween the transcriptional machinery and methylated DNA,
specifically recognizing 5-methylcytosine in the context of a
CpG dinucleotide and imposing a chromatin structure that is
unfavorable to transcription. Two types of methylated DNA
binding motifs have been identified: methyl-CpG binding do-
mains (MBD) and C2H2 zinc fingers. Vertebrate proteins in
mammals that contain an MBD domain are MBD1 to -4 and
MeCP2 (10). MBD1, MBD2, and MeCP2 interact with differ-
ent corepressor complexes, but each depends for its transcrip-
tional repression activity on a different chromatin-modifying
complex (18, 29, 30, 41, 49). Kaiso, with three C-terminal zinc
fingers, is a distinct member of the class that recognizes a
consecutive pair of methyl-CpG sequences (33, 34) but also has
binding specificity for the nonmethylated sequence CTGCNA
(6). Like the MBD proteins, Kaiso can behave as a DNA
methylation-dependent transcriptional repressor (6, 33) and
recruit a histone deacetylase-containing corepressor complex
(N-CoR) to methylated sites in the genome (53).
Kaiso was first isolated through its ability to interact with the
Armadillo-repeat catenin p120 (5). The interaction was sur-
prising as p120-catenin associates with cadherins at the cell
membrane, whereas Kaiso behaves as a DNA-binding protein.
This raised the possibility that the p120-catenin:Kaiso pair may
functionally resemble the -catenin:LEF/TCF system by par-
ticipating in the transmission of extracellular signals from the
cell membrane to the nucleus, where Kaiso could act as a
regulator of target genes (1). Immunostaining experiments
have shown that Kaiso can be either nuclear or cytoplasmic, its
intracellular localization and levels of expression being deter-
mined by unidentified factors that respond to the cellular mi-
croenvironment (44). Support for Kaiso’s role in responding to
signals from the cell surface has come from studies in Xenopus
which showed that the xWnt11 gene, a target of noncanonical
Wnt signaling, is regulated by Kaiso (22). Kaiso-mediated re-
pression of xWnt11 and other targets of canonical Wnt signal-
ing are antagonized by p120-catenin (22), which is consistent
with the finding that p120-catenin competes with DNA for
access to the Kaiso zinc finger domain (6). Repression of the
Xenopus genes xWnt11 and Siamois appears to be DNA meth-
ylation independent (32), but Kaiso has also been shown to
repress transcription of methylated genes (33, 53). In addition,
Kaiso has been detected in HeLa cells as part of a multiprotein
histone deacetylation complex, where it directly interacts with
N-CoR. Likely Kaiso target genes in mammalian cells include
S100A4, MTA2, Matrilysin, and the synapse-specific gene Rapsyn
(22, 37, 45). Interestingly, Kaiso is reported to be a transcriptional
activator at the Rapsyn promoter (37).
Methyl-CpG binding proteins have been implicated in a
variety of cellular processes using the technique of gene dis-
ruption in mice. For example, Mbd4 deficiency causes an in-
crease in mutation at methyl-CpG sites and reduces the apo-
ptotic response to DNA damage (28, 40, 51), Mbd2 deficiency
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causes premature activation of the interleukin-4 and gamma
interferon genes in T cells (14), and Mbd1 deficiency causes
defects in neurogenesis (54). A lethal phenotype is demon-
strated by Mecp2-null mice, which acquire neurological defects
at 6 weeks of age and show misregulation of several genes in
brain tissue (3, 12, 26, 31). Depletion of Kaiso in Xenopus
embryos leads to premature gene activation at the blastula
stage (38), abnormal gastrulation, and early embryonic lethal-
ity. It was therefore proposed that Kaiso is an essential com-
ponent of a developmental gene regulatory pathway that con-
trols vertebrate morphogenesis (22). Here, we show that
deletion of the mouse Kaiso gene does not result in any obvi-
ous phenotype. Nor does absence of Kaiso detectably alter
expression of the putative target genes Wnt11, S100A4, MTA2,
or Rapsyn. Kaiso is therefore dispensable for mouse morpho-
genesis. Kaiso-deficient mice do, however, show resistance to
intestinal tumorigenesis when bred onto an ApcMin/ genetic
background, indicating a role in tumor development. This ef-
fect is reminiscent of the tumor resistance seen in Mbd2-
deficient mice (39). Consistent with a contribution of Kaiso
expression to tumorigenesis, we also observe elevated Kaiso
expression in mouse intestinal tumors and expression in a
series of human colorectal tumors. Together, our data indicate
that Kaiso augments tumorigenesis in the colon.
MATERIALS AND METHODS
Northern blots. Total RNA was isolated from mouse tissues by using RNABee
according to the manufacturers’ protocol (Biogenesis, Ltd.), and 30 g was
loaded per lane for Northern blotting. RNA was transferred to Hybond-N
(Amersham Pharmacia Biotech), and all blots were hybridized in Modified
Church and Gilbert buffer (7% sodium dodecyl sulfate [SDS], 0.5 M phosphate
buffer [pH 7.2], 10 mM EDTA) with denatured herring sperm DNA at 65°C.
After overnight hybridization blots were washed in 0.3 M NaCl–0.03 M sodium
citrate–1% SDS at 65°C. Signal was detected by using a Storm PhosphorImager
(Molecular Dynamics), and analysis was performed using ImageQuant software
(V3.3). Gene specific probes were prepared by PCR amplification of coding
sequences from either wt genomic DNA or cDNA. A 334-bp Rapsyn exon 2
probe was amplified with the following primers: 5-CCGTGGTCCAGATTG
ATACT and 5-TGGACCTGGGCGTAGAAACT. A 572-bp MTA2 exon 1-2
cDNA probe was amplified with the following primers: 5-CCGGGTGGGAGA
TTACGTC and 5-CCACCACGAGAAACTGATC. A cDNA of mouse S100A4
gene was excised from p271 plasmid as described previously (9).
Chromatin immunoprecipitation. Chromatin was prepared from Kaiso-FLAG
animals (livers and lungs) as described by the manufacturer (http://www.upstate
.com/misc/protocols.q.prot.e.chips/ChromatinImmunoprecipitationChIPs
AssayKit). Chromatin was immunoprecipitated with 20 g of anti-Flag antibody
(M2; Sigma) overnight at 4°C on a rotating platform. Subsequent steps for recovery
of the immunoprecipitated DNA were performed as described in the Upstate pro-
tocol cited above. The PCR conditions consisted of 95°C for 5 min, followed by 25
cycles at 95°C for 30 s, 64°C for 30 s, and 72°C for 30 s. The IAP chromatin
immunoprecipitation primers were 5-AGCCGCCCCCACATTCGCCGT and
5-TCACTCCCTGATTGGCTGCAGC.
Reverse transcriptase PCR. Total RNA was isolated from mouse liver by
TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. For first-
strand synthesis, the RevertAid First-Strand cDNA synthesis kit (Fermentas) was
used. Total RNA (1 to 1.5 g) plus 0.2 g of random hexamers were incubated
for 5 min at 70°C, chilled, and mixed with 4 l of 5 reaction buffer, 2 l of 5
mM deoxynucleoside triphosphates, and 200 U of RevertAid M-MuLV reverse
transcriptase. The reaction mix was incubated at 25°C for 5 min at 42°C for 60
min and then at 70°C for 10 min. Freshly synthesized cDNA was used as a
template for PCR. The PCR conditions consisted of 95°C for 5 min, followed by
25 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The primers for IAP
Q-PCR were 5-TGTACCCCGAGCACCAAGAGT and 5-ATAGGATCC
GGGCCATACCAT. The primers for 18S rRNA Q-PCR were 5-AGACGA
TCAGATACCGTCGTA and 5-TGAGGTTTCCCGTGTTGAGTCA. The
primers for Wnt11 were 5-AGCTGGAGGGCCTGGTGTCTGC and 5-AGG
CCCGGGCGATGGTGTG.(
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Real-time PCR was performed with an ABI Prism 7000 using SYBR Green I.
Mean values of CT (cycle threshold) and standard deviations were calculated for
duplicate samples. Analysis was performed with independent RNA samples from
two mice, with equivalent results. Depicted data represent analysis of one animal.
Clinical samples. Informed consent was obtained from patients to obtain
normal and malignant tissue prior to surgical resection of their colon carcinomas
in accordance with and under the supervision of the Institutional Review Board
of the Montefiore Medical Center.
Kaiso gene disruption. A mouse genomic DNA fragment containing the Kaiso
locus was identified through screening of the RPCI-21 genomic PAC library with
32P-labeled Kaiso cDNA. Clone 382-D23 was subcloned to generate the targeting
vector. We first cloned two fragments (all coordinates assume the Kaiso trans-
lational start ATG codon as 0): a SmaI fragment (	2041 to 	116) and a SacII
fragment (2391 to  3673) were subcloned into the pBS/SK	 plasmid. A
neo/tk selectable marker cassette was created by excising the tk gene from
plasmid pBT/SPtk(XbaI) using XbaI and cloning it into pBT/MTneo(RI)Ver-
sion17 at the EcoRV site. An XbaI-HindIII fragment containing the neo and tk
genes was then cloned into pBS246 (Invitrogen). A NheI-ScaI fragment from the
resulting plasmid was subcloned into pBS246 to generate pBS246-neo/tk, which
contained three loxP sites flanking a BamHI site and the neo/tk cassette. A
C-terminal Flag tag was added to the Kaiso cDNA (	115;2394) by introducing
a synthetic double-stranded Flag oligonucleotide at an artificially introduced
EcoRI site at position 2013. The resulting tagged Kaiso cDNA was subcloned
into pBS246-neo/tk through BamHI. Finally, Kaiso cDNA and neo/tk were
excised by NotI and cloned into the NotI site of plasmid pBS/SK	. The vector
was linearized prior to transfection.
We carried out gene targeting in the embryonic stem (ES) cell line E14 TG2a
from mouse substrain 129/Ola. Cells were grown on gelatinized dishes without
feeder cells in the presence of recombinant human LIF (a gift from A. Smith) in
standard ES cell conditions. ES cells (10e7cells) were transfected with the lin-
earized targeting vector (250 g of DNA in 0.8 ml of HEPES buffered saline) by
electroporation (800 V, 3 F; Bio-Rad Gene Pulser) and plated in 10-cm dishes
at 5  106 cells per dish. Correctly targeted clones were identified by PCR with
the following primers: 1, TCAAAGGAAGGCGACCAAGGAGAT; 2, AGC
AGTACCATCCTGTTCTG; 3, CTGTCACAGGTTAAAAGC; 4, GTAAGA
TTCTGGTATTAT; and 5, ATAGTTTAAAGGCATATAGTGGCC. The posi-
tion of the primers is shown in Fig. 1A. Three primer sets were used for the
amplification: 1-5, 1-2, and 3-4. The extension time was calibrated so that only a
short (620-bp) DNA fragment was amplified when the 1-5 set was used without
amplification of Kaiso coding sequences or the neo/tk cassette. The LoxP flanked
allele was identified as an 880-bp band in the 1-2 set, while the intact locus gave
rise to a smaller (676-bp) band.
Correctly targeted ES cell clones were passaged the day before injection and
injected into blastocysts from naturally mated C57BL/6 females at 3.5 days
postcoitum. Injections were performed in M2 medium (Sigma) with 10 to 15 ES
cells being injected into each blastocyst before transfer to pseudopregnant re-
cipient females (6 to 12 blastocysts per recipient). Chimeric pups were identified
by their agouti coat color and, on maturity, were mated with C57BL/6 mice. Since
Kaiso is X linked, all agouti F1 females were heterozygous for the floxed allele.
This was confirmed by PCR and Southern blot. We crossed heterozygous females
with “deleter” mice that expressed cre recombinase under the cytomegalovirus
promoter. The DNA fragment between two loxP sites was deleted in the off-
spring. After inbreeding, the line was maintained in the homozygous state on a
C57BL/6 genetic background.
Assay for intestinal tumorigenesis. Kaiso-null mice segregating equally for
C57BL/6 and Ola129 genomes were mated to ApcMin/mice on an inbred C57BL/6J
background. Progeny from this cross were then interbred to generate cohorts of
ApcMin/, Kaiso/y (20 mice plus 23 for the 180-day experiment), and ApcMin/
Kaiso	/y (21 mice plus 18 for the 180-day experiment) mice. These cohorts were
therefore segregating for C57BL/6 (75%) and 129/Ola (25%) genomes. All mice
were confirmed as congenic for the C57BL/6 Mom-1 allele via PCR analysis. Two
experiments were performed: (i) mice were sacrificed when they displayed overt
signs of illness and (ii) mice were culled at 180 days. Intestinal tumor burden was
determined by removing the entire intestine and mounting en face. Preparations
were fixed in methacarn (methanol-chloroform-glacial acetic acid [4:2:1]), and the
lesion number and size were scored macroscopically.
Intestines fixed in methacarn were wound into a “gut roll” and paraffin-
embedded for histological analysis and immunohistochemistry. To determine
crypt size and the levels of apoptosis and mitosis, gut rolls were stained with
hematoxylin and eosin, and then the numbers of apoptotic bodies and mitotic
figures were determined. Crypt size, apoptotic bodies, and mitotic figures in
normal crypts were scored per 25 full crypts. For each adenoma, the number of
apoptotic bodies per 500 cells was scored, and for each mouse at least three
adenomas were scored, producing an average value per mouse. At least three
mice were used for each time point.
Western blots. Frozen aliquots of human colorectal tissue were thawed, and
total cellular protein was isolated in immunoprecipitation buffer (50 mM Tris-
HCl [pH 7.5], 150 mM NaCl, 1% IGEPAL, 0.5% sodium deoxycholate, 1 mM
EDTA, 5 g of leupeptin/ml, 1 g of aprotinin/ml, 1 M phenylmethylsulfonyl
fluoride, and 0.7 g of pepstatin/ml). Equal protein amounts were then subjected
to SDS-polyacrylamide gel electrophoresis and Western blotting with anti-Kaiso
monoclonal antibody 6F (Upstate, Lake Placid, NY). Colo 201, Colo 205, Colo
320, DLD-1, HCT15, HCT116, and SW48 cells were grown in Dulbecco modified
Eagle medium with 10% fetal bovine serum (Gemini Biosciences). Cells were
lysed in 50 mM Tris-HCl (pH 7.4)–NP-40 1%–sodium deoxycholate 0.25%–NaCl
150 mM buffer with protease inhibitors and assayed by Western blotting with the
Kaiso 6F monoclonal antibody.
Gel shift analysis of cell line extracts. Kaiso-deficient mouse tail fibroblasts
were prepared and immortalized with simian virus 40 virus as described previ-
ously (11). The CG11 (nonmethylated) and MeCG11 (methylated) probes were
prepared and labeled as described previously (27). The gel shift was performed
in agarose gels as described previously (11).
Immunohistochemistry. Colorectal tumors and matched normal mucosa from
Muc2	/	 mice were fixed in 4% neutral buffered formalin, processed, embedded
in paraffin wax, sectioned, and stained with hematoxylin and eosin. For Kaiso
expression, tissue sections were deparaffinized and rehydrated through a xylene
and graded ethanol series. For antigen retrieval, slides were immersed in citrate
buffer (pH 6) and brought to boil in a steamer for 20 min. Slides were cooled to
room temperature in a running water bath for 15 min and then incubated with
3% hydrogen peroxide in methanol to quench endogenous peroxidase activity for
15 min. After three washes with phosphate-buffered saline (PBS), slides were
incubated with permeabilization buffer (0.5% Triton X-100, 20 mM HEPES [pH
7.4], 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose) for 20 min at room temper-
ature. After one wash with PBS, slides were incubated with universal blocking
solution (CAS Block; Zymec Laboratories, California) for 10 min at room tem-
perature. The solution was drained, and primary immunoglobulin G1 (IgG1)
mouse monoclonal anti-Kaiso antibody (1:200 dilution in PBS; Upstate) or
mouse IgG was added as a negative control (1:200 dilution in PBS; Jackson
Immunoresearch). Slides were then incubated at 4°C overnight. After three
washes with PBS, the slides were incubated for 1 h with biotinylated goat anti-
mouse antibody (1:250 dilution in PBS; Zymed Laboratories) at room temper-
ature. Slides were washed three more times with PBS and then incubated for 1 h
with preformed avidin-biotinylated peroxidase complex (Vectastain ABC; Vec-
tor Laboratories) at room temperature. Color was developed by the addition of
diaminobenzoate chromogen peroxidase substrate (Vector Laboratories). Slides
were then counterstained with 10% Harris hematoxylin (Lerner Laboratories), de-
hydrated through a graded ethanol series and xylene, mounted (VectaMount; Vec-
tor Laboratories), and visualized by using a light microscope (Zeiss Axioskop).
Neural stem cells assay. Monolayer differentiation to neuroectoderm and
isolation of neural stem cell lines was performed as described previously (4, 52).
Antibodies against RC2 and Nestin were obtained from the Developmental
Studies Hybridoma Bank, the anti--tubulin III was obtained from Covance, and
the anti-Gfap antibody was obtained from Sigma.
Confocal immunofluorescence. Kaiso-deficient cells were plated at 103 cells per
coverslip and grown for 12 h. A plasmid expressing a green fluorescent protein
(GFP)-Kaiso fusion was generated by inserting the human Kaiso coding region in
frame with a FLAG coding sequence into pFLAG-CMV2 vector (Sigma) with
subsequent cloning of the GFP gene in frame at 3 end of Kaiso to give an N-
terminal GFP tag. The cells were transfected with the GFP-Kaiso construct by using
Lipofectamine reagent (Invitrogen) according to the manufacturer’s instructions.
Two days after transfection the cells were fixed in 3% paraformaldehyde for 30 min,
followed by two washes with PBS-glycine, permeabilized in 0.2% Triton X-100 for 5
min, and blocked with 3% milk solution. Monoclonal antibody 6H11 against p120-
catenin (kindly provided by A. B. Reynolds) was used at 2 g/ml. Secondary goat
anti-mouse IgG labeled with Alexa 594 (Molecular Probes) was diluted 1:600. The
slides were mounted with Vectashield reagent (Vector Laboratories) and examined
with Leica DM IRE 2 confocal microscope with a100 oil immersion objective lens.
RESULTS
Deletion of the Kaiso gene causes no overt phenotype in
mice. The X-linked Kaiso locus was targeted in male ES cells to
generate a cell line with a “floxed” allele of Kaiso that could be
conditionally deleted (Fig. 1A; see Materials and Methods).
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The genomic structure at the targeted Kaiso allele was con-
firmed by Southern blot (not shown) and PCR analysis with a
set of locus-specific primers (Fig. 1B). Chimeric mice derived
from the Kaiso-null cells were bred, and germ line progeny
were identified. A null Kaiso allele was then generated by
intercrossing with Cre-expressing mice, leading to deletion of
the single loxP flanked coding exon of the Kaiso gene. Subse-
quent progeny were intercrossed to generate Kaiso-null ani-
mals that lacked Kaiso mRNA as determined by a Northern
blot assay (Fig. 1C). Absence of the 100-kDa Kaiso protein
was confirmed in liver nuclear extracts derived from the mu-
tant mice by using antisera raised against amino acids 124 to
492 of Kaiso (Fig. 1D). We further showed that the protein-
DNA complex seen in wild-type (wt) mice between Kaiso and
the methylated probe MeCG11 (KGB) (33) was absent in
extracts from mutant mice (Fig. 1E). An anti-Kaiso antibody
supershifted the wt KGB complex but had no effect on com-
plexes formed in mutant extracts (Fig. 1E). Kaiso-null mice
showed no overt phenotype and could be maintained as a
robust line for 
10 generations. The mice were of normal
weight and gave birth to litters of normal size.
Analysis of Kaiso-null mice at the cellular level. The core-
pressor N-CoR has been biochemically purified in association
with Kaiso and shown to mediate Kaiso repression (53). Since
N-CoR has been implicated in development of the central
nervous system, erythrocytes, and thymocytes (16), we sought
to determine whether Kaiso deficiency affected these tissues.
Analysis of blood cells in Kaiso-null mice showed no significant
difference from wt mice with respect to the composition of the
leukocyte and erythrocyte fractions or erythrocyte morphology
(see Fig. S1 in the supplemental material).
We next tested the developmental potential of Kaiso-null
stem cells, since N-CoR is implicated in development of the
nervous system (16). Also, mice deficient for the methyl-CpG
binding protein Mbd1 are viable and fertile but show a defect
in adult neurogenesis and hippocampal function, and Mbd1-
null neural stem cells show reduced neuronal differentiation
compared to wt cells (54). To test for a comparable phenotype
in Kaiso-null cells, ES cells in which GFP is expressed from the
Sox1 locus (52) were targeted with the floxed Kaiso construct.
Properly targeted cells were transfected with a Cre-expression
plasmid to induce deletion of the Kaiso gene. The genotype
of targeted cells was confirmed by PCR and Southern blotting
FIG. 2. Kaiso-null cells show no defects in neural differentiation.
(A) Wild-type or Kaiso-deficient ES cells expressing GFP from the
Sox1 locus were induced toward neural differentiation for 3, 4, 5, 6, 7,
or 8 days (D3, D4, etc.) and fluorescence-activated cell sorted for GFP
expression. The experiment was performed in triplicate, with average
values ( the standard error of the mean) plotted. (B) Kaiso gene
expression was analyzed by RT-PCR in wt and null (clone A and B)
sorted Sox1-positive cells. (C to F) Wild-type (C and E) and Kaiso-null
(D and F) cultures were stained for -tubulin (C and D) or Gfap (red)
and DAPI (4,6-diamidino-2-phenylindole; blue) (E and F) after 12
days of monolayer differentiation. (G to N) Wild-type (G, I, K, and M)
and Kaiso-null (H, J, L, and N) neural stem cells were stained for
Nestin (G and H) and RC2 (I and J) or were induced to differentiate
and stained for -tubulin III (K and L) or Gfap (M and N). Cells were
counterstained with DAPI (blue). Scale bars: 100 m (C, D, E, F, M,
and N) and 50 m (G, H, I, J, K, and L).
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FIG. 3. No evidence for abnormal gene expression in Kaiso-null animals. (A) Total RNA from four different animals born in two independent
families was isolated from wild-type (WT) and Kaiso-null (KO) strains. Sources of RNA were brain, liver, spleen, and muscle. The same blot was
hybridized with S100A4 and Mta2 probes. Separate blots were prepared with muscle RNA and hybridized with a Rapsyn probe. Normalization of
the amount of RNA loaded was performed by reprobing with -actin (S100A4; Mta2) or S26 ribosomal protein (Rapsyn) probes. (B) In the left
panel, chromatin immunoprecipitation was performed with M2 anti-FLAG monoclonal antibodies (M2 lanes) and chromatin was prepared from
kidney of wild-type (WT) and Kaiso-null (KO) animals. PCR products amplified with IAP-specific primers from chromatin immunoprecipitated
with or without (“no Ab”) the addition of antibodies are designated. Amplification without DNA (	) and with kidney genomic DNA () were
used as negative and positive controls, respectively. PCR products were fractionated on 1% agarose gels. In the right panel is shown IAP expression
analysis. RNA from liver of wild-type (WT) and Kaiso-null (KO) animals was either transcribed () or not transcribed (	) by reverse transcriptase
(RT). Subsequent PCR amplification of IAP cDNA and control 18S cDNA produced DNA fragments that were resolved on agarose gels. Different
dilutions of cDNA were used for PCR amplification as depicted. (C) Semiquantitative RT-PCR with serial dilutions of cDNA from WT or KO
heart were amplified by using Wnt11-specific primers and compared to 18S rRNA-specific primers used to amplify the same samples. (D) Quan-
titative “real-time” PCR analysis of Wnt11 mRNA abundance in the hearts, livers, and testes of WT and KO mice. “Delta Ct” expresses the
difference in cycle thresholds between Wnt11 and 18S amplification rates.
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(as in Fig. 1B), and loss of Kaiso expression was verified
by reverse transcription-PCR (RT-PCR) (Fig. 2B). Both
Kaiso/y Sox1GFP and Kaiso	/y Sox1GFP ES cell lines were
then induced to differentiate into neural ectoderm as de-
scribed previously (52). Since Sox1 is a specific marker of
neural specification, cells that become GFP positive have
differentiated into neural precursor cells and can be quan-
tified by fluorescence-activated cell sorting analysis. We
found that both Kaiso/y Sox1GFP and Kaiso	/y Sox1GFP ES
cells differentiated into Sox1GFP-positive neural precursors at
similar frequencies (Fig. 2A). After 12 days, cultures were fixed
and stained for markers of postmitotic neurons (-tubulin III;
Fig. 2C and D) and astrocytes (GFAP; Fig. 2E and F). Both
astrocytes and neurons were produced efficiently in Kaiso-null
cultures, indicating that Kaiso is not important for cell fate
decisions by this assay.
In order to study whether Kaiso plays a role in maintenance
of stem cell state and self-renewal, we made pure neural stem
cell lines from Kaiso/y and Kaiso	/y ES cells (4). Kaiso	/y
neural stem cells were efficiently maintained through multiple
passages (
20) mirroring the wild-type neural stem cells in
morphology and proliferation (data not shown). Cells of both
genotypes expressed neural stem cell markers Nestin (Fig.
2G and H) and RC2 (Fig. 2I and J). Multipotency was
verified by efficient differentiation into postmitotic neurons
(Fig. 2K and L) and astrocytes (Fig. 2M and N) that were
indistinguishable from wild-type cultures. We conclude that
Kaiso function is not important for neural specification, neural
stem cell viability, or neuronal and astroglial cell differentia-
tion ex vivo.
We also addressed the effects of Kaiso on localization of p120-
catenin in fibroblasts derived from Kaiso-null mice. Transient
transfection of a construct expressing a GFP-Kaiso fusion protein
had no detectable effect on the cytoplasmic localization of p120-
catenin, since transfected and neighboring untransfected cells
were indistinguishable in this respect (see Fig. S2 in the supple-
mental material). Kaiso localization in this assay was predomi-
nantly nuclear. Our findings are compatible with a previous report
that p120-catenin and Kaiso do not colocalize (44).
Kaiso deficiency does not affect expression of candidate tar-
get genes. Kaiso has been implicated in the regulation of sev-
eral genes using mammalian cultured cell systems. We ini-
tially sought to determine whether Kaiso deletion influenced
transcription of the putative targets S100A4, Mta2, and
Rapsyn (35, 37, 53) in tissues from Kaiso-null mice. Northern
blot analysis revealed no change in expression of Mta2 in
RNA from brain, liver, or spleen (Fig. 3A). Rapsyn mRNA,
which is normally expressed in muscle, was not affected by
the absence of Kaiso and S100A4 expression, which is high
spleen (9), was also indistinguishable between wt and Kaiso-
null animals (Fig. 3A). To look for global effects of Kaiso
deficiency, we examined expression of IAP transposable el-
ements, which is normally suppressed by DNA methylation
(50). Chromatin immunoprecipitation established that
FLAG-tagged Kaiso expressed from the floxed allele was
associated with IAP element sequences in chromatin from
liver (Fig. 3B). Semiquantitative PCR analysis, however,
failed to detect any difference in IAP expression when wt
and Kaiso-null liver RNA preparations were compared (Fig.
3B). A particularly well-characterized Kaiso target gene is
xWnt11, which binds Kaiso and is upregulated by its absence in
Xenopus embryos (22). Moreover, the human Wnt11 gene has
been immunoprecipitated from cross-linked HeLa cell chromatin
by anti-Kaiso antibodies (22). Examination of Wnt11 expression
in Kaiso-null tissues by RT-PCR showed no obvious effect of
Kaiso deficiency by either semiquantitative RT-PCR using heart
cDNA (Fig. 3C) or quantitative real-time PCR using cDNA
FIG. 4. Kaiso deficiency decreases tumor size and increases life
span of ApcMin/ mice. (A) Kaplan-Meier survival plot of ApcMin/
Kaiso/y (solid line) and ApcMin/ Kaiso	/y (hashed line) mice. ApcMin/
Kaiso	/y mice live significantly longer (median, 317 days; gray vertical line)
than both ApcMin/ Kaiso/y (median, 217; black vertical line, P  0.006
[log rank]). (B) Tumor number is not altered by Kaiso deficiency. Boxplots
show numbers of adenomas per mouse at 180 days and at death. The
horizontal boxed line represents the median. Gray boxes, ApcMin/
Kaiso/y; open boxes, ApcMin/ Kaiso	/y. No significant differences were
observed between ApcMin/ Kaiso/y and ApcMin/ Kaiso	/y mice at either
180 days (P  0.10 [Mann-Whitney], n  20) or at death (P  0.62
[Mann-Whitney], n  20). (C) Tumor size, measured by area, is reduced
in Kaiso-deficient mice at 180 days (P 0.001 [Mann-Whitney], n 114)
but not death (P  0.55 [Mann-Whitney], n  239). Gray bars, ApcMin/
Kaiso/y; open bars, ApcMin/ Kaiso	/y. Bars represent the standard error
of the mean.
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from heart, liver, and testis (Fig. 2D). We conclude that in
the mouse Kaiso does not play a dominant role in the
regulation of these candidate target genes.
Kaiso-deficient ApcMin/ mice exhibit delayed intestinal tu-
morigenesis. Three lines of evidence led us to examine a pos-
sible role for Kaiso in intestinal cancer. First, accumulating
data indicate a critical role for DNA methylation-dependent
gene silencing in the pathogenesis of colorectal cancer (23).
Second, Kaiso DNA binding and transcriptional activity is at-
tenuated by interaction with the p120 catenin protein (22),
which is lost in ca. 25% of colorectal tumors, and is abnormally
expressed or localized in another 40% of tumors (20, 47).
Third, Kaiso is implicated in Wnt signaling (8, 19, 22, 32, 45),
which is often disrupted in intestinal tumors. To test for the
involvement of Kaiso in colorectal cancer, we used the ApcMin/
mouse, which is a model for human familial adenomatous polyp-
osis (46). ApcMin/ mice acquire multiple intestinal polyps within
the first 6 months of life. DNA methylation has been previously
implicated in this model since deficiencies of either the DNA
methyltransferase Dnmt1 (7, 24) or the methyl-CpG binding pro-
tein Mbd2 (39) confer striking resistance to tumorigenesis. We
therefore crossed Kaiso-null mice with ApcMin/ mice and as-
sessed survival and tumor burden in the resulting male Kaiso	/y
ApcMin/ offspring. A significant increase in the survival of the
Kaiso	/y Apc/Min mice compared to Kaiso/y Apc/Min mice was
recorded (Fig. 4A). Tumor burden at 180 days and at death was
comparable between the two genotypes (Fig. 3B), but the size of
polyps was significantly less at 180 days in mice lacking Kaiso
(Fig. 4C). Examination of adenomatous polyps from wt and
Kaiso-null Min mice showed no significant difference in the mi-
totic indices or in levels of apoptosis in either normal epithelium
or adenomas (see Fig. S3A and B in the supplemental material),
arguing that the reduced growth rate of Kaiso-null intestinal
polyps is not caused by a lower rate of cell division or
increased cell death.
As a further test for a relationship between Kaiso and in-
testinal tumorigenesis in mice, we examined Kaiso expression
levels in colorectal tumors from the Muc2	/	 mouse model,
which develops invasive colorectal tumors akin to those of
patients with inflammatory bowel disease. The latter have been
linked to silencing by CpG island hypermethylation (13, 15, 43,
48). We performed immunohistochemistry and Western blots
on Muc2	/	 tumors and matched normal mucosa controls
from the same mice. By both assays, Kaiso expression was
significantly increased in tumors compared to controls (Fig. 5).
Moreover, Kaiso was predominantly nuclear in tumor samples
(Fig. 5A), unlike the predominantly cytoplasmic staining re-
ported in human tumors and normal tissues (44). We went on
to ask whether human colon carcinomas also express Kaiso.
Kaiso protein levels were examined in 14 human primary colo-
rectal tumors and their matched normal colonic mucosa. Kaiso
was detectable in all tumors with variable expression ratios
between polyps and normal mucosa (see Fig. S4 in the supple-
mental material).
FIG. 5. Kaiso expression is elevated in murine intestinal tumors.
(A) Immunohistochemistry with an anti-Kaiso antibody 6F in colonic
tumor and matched normal mucosa from Muc2	/	 mice at the indicated
magnification factors. (B) Western blots performed with anti-Kaiso
and antiactin antibodies in two pairs of Muc2	/	 intestinal tumors
compared to matched normal mucosa.
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DISCUSSION
The mild phenotype of Kaiso-null mice is surprising given
the severe effects of its absence in Xenopus (22, 38) and its
proposed role as an essential component in a regulatory path-
way that controls vertebrate morphogenesis (22). This may be
due to differences in the roles of DNA methylation in control-
ling the zygotic gene program in mice and frogs. In frogs,
methylation is critical for the silencing of genes though the first
eight zygotic cell divisions. In contrast, the paternal genome of
mice is actively demethylated before the first zygotic cell divi-
sion, whereas the maternal genome becomes passively demeth-
ylated through cleavage divisions. Zygotic transcription is de-
tected at the two-cell stage in mice, but is not activated until
the 5,000 cell mid-blastula transition in frogs. Thus, the role
of Kaiso in ensuring delayed activation of genes in frogs may
have no counterpart in mice.
Regarding the role of Kaiso in transcriptional repression, we
were surprised to find no difference in expression of four genes
that were previously identified as Kaiso targets (S100A4, Mta2,
Rapsyn, and Wnt11). This suggests either that these genes are
not targets of Kaiso-mediated repression in the mouse or that
there is a level of redundancy in their control. It is not possible
to predict which proteins might substitute for the absence of
mouse Kaiso, but the related protein CIBZ/Zenon may be a
potential candidate (21, 42). It is clear that deficiency of N-
CoR is not equivalent to loss of Kaiso, as Kaiso-null mice show
none of the abnormalities observed in N-CoR-null embryos,
which die before birth (16). N-CoR is also implicated in the
regulation of neurogenesis and in blood differentiation (16),
both of which appear normal in Kaiso-null mice.
Our data implicate Kaiso in intestinal tumorigenesis, since
its absence inhibits the formation of adenomatous polyps in a
mouse model of familial adenomatous polyposis, and both
mouse and human colorectal tumors express Kaiso. Given the
ability of Kaiso to mediate DNA methylation-dependent tran-
scriptional repression (33, 53) and the known dependence of
mouse intestinal tumorigenesis on Dnmt1 (7, 24) and Mbd2
(39), it is tempting to speculate that Kaiso plays a part in the gene
silencing that contributes to the cancer phenotype. Studies of
repression of the MTA2 gene in HeLa cells are compatible with
this view (53). MTA2 is a component of the ubiquitously ex-
pressed Mi-2/NuRD complex, and its DNA methylation-depen-
dent repression in HeLa cells is therefore likely to be an abnormal
gene silencing event of the kind that is common in permanent cell
lines (2) and cancer cells (17). Therefore, Kaiso may mediate
abnormal gene silencing that occurs in cancer cells. The finding
that Kaiso-null Min tumors exhibit the same mitotic and apoptotic
indices as wt Min tumors suggests that Kaiso does not delay tumor
growth. It is therefore possible that Kaiso augments the early
stages of tumorigenesis. Kaiso has been implicated in Wnt signal-
ing (8, 19, 22, 32, 45), which is important for the normal differ-
entiation program of intestinal epithelium (36). Since polyps in
Min mice are invariably Apc null and therefore hyperactive in
Wnt signaling (25), the absence of Kaiso may reduce the impact
of this defect and therefore constrain tumor development. Future
work will seek to identify the range of Kaiso target genes in the
intestine that may contribute to such an effect.
The observation that deficiency of Kaiso attenuates tumor-
igenesis suggests Kaiso as a possible target for anticancer ther-
apy, as has been suggested for both Dnmt1 and Mbd2. Al-
though the delay of tumorigenesis caused by absence of Kaiso
is less pronounced than that due to Dnmt1 or Mbd2, Kaiso has
the attraction that its absence does not lead to any deleterious
phenotype in the mouse. This contrasts with the embryonic
lethality caused by absence of Dnmt1 (24) and abnormal gene
expression caused by absence of Mbd2 (14) and may reduce
the likelihood that Kaiso antagonists will be toxic.
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